--- title: "Niki BioSolutions (NIKI) news: merger" url: "https://aibio.space/companies/niki-biosolutions/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "NIKI merger news: Aptorum Group (now Niki BioSolutions) shareholders approve DiamiR merger. Niki BioSolutions, Inc. (NASDAQ: NIKI), United States." --- NIKI Niki BioSolutions, Inc. NASDAQ · United States # Niki BioSolutions (NIKI) news NIKI merger news Listings · 2026-08-07 ## [Aptorum Group (now Niki BioSolutions) regains Nasdaq bid price compliance](https://aibio.space/news/aptorum-group-now-niki-biosolutions-regains-nasdaq-bid-price/) Nasdaq's August 4, 2026 letter says the closing bid price held at $1.00 or more for ten straight business days. The 8-K gives no share price, and the company's latest annual report shows $3.5 million of cash and a material weakness in its controls. ## Latest Niki BioSolutions news 1. 2026-06-10 Listings [Aptorum Group (now Niki BioSolutions) shareholders approve DiamiR merger](https://aibio.space/news/aptorum-group-now-niki-biosolutions-shareholders-approve-diamir-merger/) Shareholders of both companies approved the all-stock merger on June 9, 2026. The release gives no exchange ratio, and the company's 2025 research spending was $352,879, down from $2.2 million. ## Niki BioSolutions at a glance - **Ticker**: NIKI - **Listing**: NASDAQ - **Country**: United States - **Cash, Dec 31, 2025**: $3.5 million ### Related companies - [Metagenomi Therapeutics](https://aibio.space/companies/metagenomi-therapeutics/) NASDAQ: MGX - [Braveheart Bio](https://aibio.space/companies/braveheart-bio/) NASDAQ: BRVE - [Mustang Bio](https://aibio.space/companies/mustang-bio/) NASDAQ: MBIO - [Mirum Pharmaceuticals](https://aibio.space/companies/mirum-pharmaceuticals/) NASDAQ: MIRM - [Trevena](https://aibio.space/companies/trevena/) OTC: TRVN - [Scorpius Holdings](https://aibio.space/companies/scorpius/) OTC: SCPX - [Viking Therapeutics](https://aibio.space/companies/viking-therapeutics/) NASDAQ: VKTX - [Kiora Pharmaceuticals](https://aibio.space/companies/kiora-pharmaceuticals/) NASDAQ: KPRX ### Also on NASDAQ - [Cingulate](https://aibio.space/companies/cingulate/) CING - [Anbio Biotechnology](https://aibio.space/companies/anbio-biotechnology/) NNNN - [Wave Life Sciences](https://aibio.space/companies/wave-life-sciences/) WVE - [Genprex](https://aibio.space/companies/genprex/) GNPX - [MANNATECH INC](https://aibio.space/companies/mannatech/) MTEX - [Kardigan](https://aibio.space/companies/kardigan/) KARD ## Niki BioSolutions annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$352,879](https://www.sec.gov/Archives/edgar/data/1734005/000121390026035484/) | [$2.2 million](https://www.sec.gov/Archives/edgar/data/1734005/000121390026035484/) | | Net income (loss) | [-$1.4 million](https://www.sec.gov/Archives/edgar/data/1734005/000121390026035484/) | [-$4.3 million](https://www.sec.gov/Archives/edgar/data/1734005/000121390026035484/) | | Cash from operations | [-$1.8 million](https://www.sec.gov/Archives/edgar/data/1734005/000121390026035484/) | [-$1.2 million](https://www.sec.gov/Archives/edgar/data/1734005/000121390026035484/) | | Cash and equivalents | [$3.5 million](https://www.sec.gov/Archives/edgar/data/1734005/000121390026037563/) | [$874,238](https://www.sec.gov/Archives/edgar/data/1734005/000121390026037563/) | Latest balance sheet, Dec 31, 2025 (6-K): cash and equivalents $3.5 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Niki BioSolutions Is Niki BioSolutions involved in a merger or acquisition? Our latest story on this, dated Jun 10, 2026: "Aptorum Group (now Niki BioSolutions) shareholders approve DiamiR merger". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/aptorum-group-now-niki-biosolutions-shareholders-approve-diamir-merger/). What is the ticker symbol of Niki BioSolutions? Niki BioSolutions, Inc. trades under the ticker NIKI on NASDAQ. Where is Niki BioSolutions listed? Niki BioSolutions, Inc. is listed on NASDAQ. What is the SEC CIK of Niki BioSolutions? The SEC Central Index Key (CIK) for Niki BioSolutions, Inc. is 1734005. Its filings are on SEC EDGAR. Which country or territory is Niki BioSolutions listed under? Our directory records Niki BioSolutions, Inc. under United States. What does Niki BioSolutions do? Our directory classifies Niki BioSolutions, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Niki BioSolutions? The ISIN recorded for Niki BioSolutions, Inc. is US6539421023. Does aibio.space cover Niki BioSolutions? aibio.space lists Niki BioSolutions, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Niki BioSolutions incorporated? SEC records list its state or country of incorporation as E9. Is Niki BioSolutions profitable? Niki BioSolutions, Inc. reported a net loss of $1.4 million for the fiscal year ended Dec 31, 2025, and used $1.8 million of cash in operations, per its annual report to the SEC. How much does Niki BioSolutions spend on research and development? $352,879 in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does Niki BioSolutions have? $3.5 million in cash at Dec 31, 2025, per its 6-K. What is the latest Niki BioSolutions (NIKI) stock news? Our latest story on Niki BioSolutions, dated Aug 7, 2026: "Aptorum Group (now Niki BioSolutions) regains Nasdaq bid price compliance". Nasdaq's August 4, 2026 letter says the closing bid price held at $1.00 or more for ten straight business days. The 8-K gives no share price, and the company's latest annual report shows $3.5 million of cash and a material weakness in its controls. [Source](https://aibio.space/news/aptorum-group-now-niki-biosolutions-regains-nasdaq-bid-price/). How long will Niki BioSolutions's cash last? From our story of Aug 7, 2026: The documents do not give a cash runway estimate or say how the company paid for its 2025 operations. [Source](https://aibio.space/news/aptorum-group-now-niki-biosolutions-regains-nasdaq-bid-price/). Is Niki BioSolutions at risk of delisting? Our latest listing story, dated Aug 7, 2026: "Aptorum Group (now Niki BioSolutions) regains Nasdaq bid price compliance". Nasdaq's August 4, 2026 letter says the closing bid price held at $1.00 or more for ten straight business days. The 8-K gives no share price, and the company's latest annual report shows $3.5 million of cash and a material weakness in its controls. [Source](https://aibio.space/news/aptorum-group-now-niki-biosolutions-regains-nasdaq-bid-price/). ## Investor discussion: Niki BioSolutions Members talk about Niki BioSolutions (NIKI). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Niki BioSolutions, newest first. Each line links the filing it comes from. 1. 2026-09-14 Mergers Reported a merger or acquisition agreement. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1734005/000121390026099695/ea030533401ex99-1.htm) 2. 2026-08-28 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3. [Source](https://www.sec.gov/Archives/edgar/data/1734005/000121390026094595/ea0302239-s3_niki.htm) 3. 2026-08-07 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1734005/000121390026086639/ea0300774-8k_nikibio.htm) 4. 2026-07-20 Mergers Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 2.01,3.03,5.02,5.03,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1734005/000121390026079416/ea029826201ex99-1.htm) 5. 2026-06-10 Listings Reported a reverse stock split. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1734005/000121390026067085/ea029405801ex99-1.htm) 6. 2026-03-06 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1734005/000121390026024709/ea028036401ex99-1.htm) 7. 2026-01-22 Mergers Reported a merger or acquisition agreement. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1734005/000121390026006378/ea027242601ex99-1_aptorum.htm) 8. 2026-01-16 Financings Set up an at-the-market program to sell shares over time. SEC Form F-3. [Source](https://www.sec.gov/Archives/edgar/data/1734005/000121390026005167/ea0272660-f3_aptorumgroup.htm) 9. 2025-10-14 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1734005/000121390025098635/ea0261107-424b5_aptorum.htm) 10. 2025-09-10 Mergers Reported a merger or acquisition agreement. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1734005/000121390025086383/ea025653301ex99-1_aptorum.htm) 11. 2025-07-22 Listings Reported a reverse stock split. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1734005/000121390025066642/ea024961501ex99-1_aptorum.htm) 12. 2025-04-30 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 20-F. [Source](https://www.sec.gov/Archives/edgar/data/1734005/000121390025037669/ea0238205-20f_aptorum.htm) 13. 2025-04-16 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1734005/000121390025032566/ea023853101ex99-1_aptorum.htm) 14. 2025-01-03 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1734005/000121390025000606/ea0226717-424b5_aptorum.htm) 15. 2024-12-20 Listings Reported a reverse stock split. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1734005/000121390024111163/ea022518701ex99-1_aptorum.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:NIKI on TradingView](https://www.tradingview.com/symbols/NASDAQ-NIKI/). ## SEC filings and registration - **SEC name**: Niki BioSolutions, Inc. - **CIK**: 1734005 - **Industry (SIC)**: Measuring & Controlling Devices, NEC (3829) - **US tickers**: NIKI (Nasdaq) - **State or country of incorporation**: E9 - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 116 VILLAGE BOULEVARD, PRINCETON, NJ, 08540 - **Phone**: 852 3953 7700 - **Former names**: Aptorum Group Ltd ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1734005/000121390026109016/ea0308307-8k_niki.htm) filed 2026-10-13 - [8-K](https://www.sec.gov/Archives/edgar/data/1734005/000121390026108572/ea0308263-8k_nikibio.htm) filed 2026-10-09 - [424B5](https://www.sec.gov/Archives/edgar/data/1734005/000121390026108567/ea0308224-424b5_nikibio.htm) filed 2026-10-09 - [8-K](https://www.sec.gov/Archives/edgar/data/1734005/000121390026099695/ea0305334-8k_nikibio.htm) filed 2026-09-14 - [8-K](https://www.sec.gov/Archives/edgar/data/1734005/000121390026097705/ea0304290-8k_nikibio.htm) filed 2026-09-04 - [S-3](https://www.sec.gov/Archives/edgar/data/1734005/000121390026094595/ea0302239-s3_niki.htm) filed 2026-08-28 - [8-K](https://www.sec.gov/Archives/edgar/data/1734005/000121390026092661/ea0302544-8k_nikibio.htm) filed 2026-08-21 - [8-K](https://www.sec.gov/Archives/edgar/data/1734005/000121390026086639/ea0300774-8k_nikibio.htm) filed 2026-08-07 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001734005), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Niki BioSolutions, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker NIKI, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Niki BioSolutions, Inc. - **Ticker**: NIKI - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US6539421023 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-NIKI/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/niki-biosolutions/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Niki BioSolutions (NIKI) news: merger", 2026-10-31, https://aibio.space/companies/niki-biosolutions/